INVO BioScience GAAP EPS of -$2.24 beats by $18.56, revenue of $2.22M misses by $0.49M

INVO BioScience reported Q3 GAAP EPS of -$2.24, beating estimates by $18.56, while revenue of $2.22M missed by $0.49M. Revenue grew 26.9% year-over-year. Adjusted EBITDA was -$1.0M, and cash was $3.7M at Q3's end, according to the company.

Original reporting
Published Nov 16, 2026, 4:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$IVF
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

Med
01

Why it matters

Traders can reassess near-term valuation and financing risk based on the revenue miss and the reported cash balance, even with a GAAP EPS beat.

02

Market read

A fresh quarterly print with explicit EPS and revenue variances plus cash provides a direct catalyst for trading the stock around the earnings window.

03

What to watch

Cash of $3.7M (about $3.10 per share) may be the dominant risk factor for positioning, potentially outweighing the EPS beat if burn rate concerns persist.

Relevance 9/10Novelty 8/10Timing: earnings release reported in the article on 2026-11-16

Background

The piece summarizes INVO BioScience’s Q3 results from a press release, focusing on GAAP EPS, revenue, adjusted EBITDA, and cash at quarter-end.

Market effects

Reinforces ongoing investor focus on revenue trajectory versus accounting-driven EPS swings in small-cap fertility/biotech names.

No clear regional spillover indicated beyond US small-cap biotech sentiment.

Limited, as the disclosure is company-specific and not tied to a global macro or regulatory event.

Counterpoint

The large GAAP EPS beat could reflect non-cash items or one-time effects; if investors believe underlying operating progress is improving, the revenue miss may be viewed as temporary.

Key entities

  • INVO BioScience, Inc.

    Reported Q3 GAAP EPS, revenue, adjusted EBITDA, and cash balance in the article.

Related articles

$IVFMed

INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA

INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA Record quarterly clinic revenues supported by both organic growth and acquisitions Seventh consecutive quarter of positive Cli

$IVFMed

INVO Fertility Inc (IVF) (Q2 2026) Earnings Call Highlights: Revenue Surges 17%

INVO Fertility Inc reported Q2 2026 revenue of $2.18 million, up about 17% year over year, driven mainly by the full-quarter contribution from Family Beginnings in Indiana and organic growth. Clinic-level Adjusted EBITDA was about $333,000. Consolidated adjusted EBITDA stayed negative at about -$1.0 million. Cash was ~$3.7 million at June 30, 2026, and the company added a $15 million equity purchase facility.

$IVFMed

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practice

$IVFMed

INVO Fertility Reports First Quarter 2026 Results

INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure 23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabiliti